Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 5
1984 5
1985 4
1988 1
1989 2
1990 1
1993 1
1994 1
1996 1
2007 2
2008 1
2009 1
2011 2
2013 1
2014 2
2015 3
2016 2
2017 3
2018 3
2019 1
2020 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Lifestyle factors and oncogenic papillomavirus infection in a high-risk male population.
Lopez-Diez E, Perez S, Carballo M, Iñarrea A, de la Orden A, Castro M, Rodríguez M, Almuster S, Montero R, Perez M, Sanchez J, Ojea A. Lopez-Diez E, et al. Among authors: ojea a. PLoS One. 2017 Sep 12;12(9):e0184492. doi: 10.1371/journal.pone.0184492. eCollection 2017. PLoS One. 2017. PMID: 28898279 Free PMC article.
Treatment of male stress urinary incontinence with the adjustable transobturator male system: Outcomes of a multi-center Iberian study.
Angulo JC, Cruz F, Esquinas C, Arance I, Manso M, Rodríguez A, Pereira J, Ojea A, Carballo M, Rabassa M, Teyrouz A, Escribano G, Rodríguez E, Teba F, Celada G, Madurga B, Álvarez-Ossorio JL, Marcelino JP, Martins FE. Angulo JC, et al. Among authors: ojea a. Neurourol Urodyn. 2018 Apr;37(4):1458-1466. doi: 10.1002/nau.23474. Epub 2018 Jan 9. Neurourol Urodyn. 2018. PMID: 29315765
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R; CUETO Group (Club Urológico Español De Tratamiento Oncológico). Ojea A, et al. Eur Urol. 2007 Nov;52(5):1398-406. doi: 10.1016/j.eururo.2007.04.062. Epub 2007 Apr 27. Eur Urol. 2007. PMID: 17485161 Clinical Trial.
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Piñeiro L, Rabadan M, Ojea A, Rodriguez-Molina J, Beardo P, Muntañola P, Gomez M, Montesinos M, Martinez Piñeiro JA; Members of Club Urológico Español de Tratamiento Oncológico. Solsona E, et al. Among authors: ojea a. Eur Urol. 2015 Mar;67(3):508-16. doi: 10.1016/j.eururo.2014.09.026. Epub 2014 Oct 6. Eur Urol. 2015. PMID: 25301758 Clinical Trial.
[Renal leiomyosarcoma].
Barros JM, Castro AM, Rodríguez B, Alonso A, Benavente J, Ojea A, Figueiredo L, Santiago P, Nogueira-March JL. Barros JM, et al. Among authors: ojea a. Actas Urol Esp. 1993 Mar;17(3):199-201. Actas Urol Esp. 1993. PMID: 8506776 Review. Spanish.
42 results